Lightnews — Scholar-powered news

Satoshi Koyama

@skoyama.bsky.social

290 followers 94 following 23 posts

Assistant Director of Bioinformatics | MGB Personalized Medicine Investigator, Cardiovascular Research Center | Massachusetts General Hospital Member of Faculty | Harvard Medical School Interested in Cardiovascular Genetics and Personalized Medicine 🧬👨‍💻

Posts Media Videos Starter Packs

Pinned

Satoshi Koyama @skoyama.bsky.social · Jan 15

We are excited to share our latest work, "Genetic Predisposition to Low-Density Lipoprotein Cholesterol and Incident Type 2 Diabetes," now published in JAMA Cardiology, led by the brilliant undergrad
x.com/akshayaravi22 🎉
jamanetwork.com/journals/jam...

Genetic Predisposition to LDL-C and Incident Type 2 Diabetes

This cohort study uses whole-exome sequencing, genome-wide genotyping, baseline lipid levels, and incident events to assess the association of genetic predisposition to low-density lipoprotein cholest...

jamanetwork.com

2 5 14

Reposted by Satoshi Koyama

Jonathan Pritchard @jkpritch.bsky.social · 2d

I want to try something again at #ASHG25 this year: I'll block some time on Thursday and Friday afternoons to meet with trainees who would be interested to chat on any topic.

I did this last year and it was great to meet a whole bunch of new people, at all career stages!

1 12 48

Satoshi Koyama @skoyama.bsky.social · 7d

Thank you, @sophie-gunn32.bsky.social!
Looking forward to working together again!

Satoshi Koyama @skoyama.bsky.social · 7d

Thanks! @jamespirruccello.com!
Looking forward to working with you!

1 1

Satoshi Koyama @skoyama.bsky.social · 7d

We’re building a team that values rigor and openness in science. If you’re interested in collaborating or working with us, please reach out to me via DM on X, Bluesky, or LinkedIn!

Satoshi Koyama @skoyama.bsky.social · 7d

I’m deeply grateful to my postdoc mentors,
@pnatarajanmd.bsky.social and Dr. Patrick Ellinor. Your unwavering support and belief on me made this a reality. Also, thank you so much for all the colleagues and friends helped this process!

1 2

Satoshi Koyama @skoyama.bsky.social · 7d

We’re also bringing genetics into clinical care. MGB Personalized Medicine now provides clinical polygenic risk score (PRS) testing using cutting-edge genotyping and PRS calibration workflows. This service is now available to institutions across the U.S.
massgeneralbrigham.org/en/research-...

Polygenic Risk Test | Mass General Brigham

The Laboratory for Molecular Medicine at Mass General Brigham offers genetic testing for Polygenic Risk.

massgeneralbrigham.org

1 2

Satoshi Koyama @skoyama.bsky.social · 7d

If you’re interested in this topic and attending #ASHG2025
@geneticssociety.bsky.social in Boston, we’d love to see you at our talk!
📅 Sat, Oct 18, 9:15–9:30 AM ET
📍 Room 253ABC (Level 2)

1 3

Satoshi Koyama @skoyama.bsky.social · 7d

As one example, we’re currently participating in a mega-scale genetic analysis of coronary artery disease involving ~4 million individuals, in collaboration with the CARDIoGRAMplusC4D consortium (cardiogramplusc4d.org) — a truly global effort.

(no title)

Visit the post for more.

cardiogramplusc4d.org

1 1

Satoshi Koyama @skoyama.bsky.social · 7d

Thanks to sustained investments in science, now we can access the data from millions of people to address a wide range of medical questions. We use large-scale genetic and clinical data to reveal disease biology and translate insights into better patient care.

1 2

Satoshi Koyama @skoyama.bsky.social · 7d

Excited to share that I’m launching a Computational Genetics Lab spanning MGB Personalized Medicine, Cardiovascular Research Center at MGH, @harvardmed.bsky.social, and @broadinstitute.org. Our research focuses on the genetics of common diseases, with a particular emphasis on cardiovascular disease.

3 5 18

Reposted by Satoshi Koyama

Mark Lindsay @markelindsay.bsky.social · Sep 4

www.broadinstitute.org/news/mass-ge...

Mass General Brigham launches genetic test to predict risk across eight cardiovascular conditions

Developed in collaboration with Broad Clinical Labs and Mass General Brigham Laboratory for Molecular Medicine, the test provides a comprehensive view of a patient’s inherited heart disease risk. div....

www.broadinstitute.org

5 9

Reposted by Satoshi Koyama

Pradeep Natarajan @pnatarajanmd.bsky.social · Jul 28

Our study led by T. Bellomo and with @aniruddhpatelmd.bsky.social describes the relationship between lipoprotein(a) and incident & progressive extracoronary atherosclerotic vascular disease www.ahajournals.org/doi/10.1161/... @ahajournals.bsky.social
@broadinstitute.org @mgbresearch.bsky.social

1 4 7

Reposted by Satoshi Koyama

Romit Bhattacharya @romitb.bsky.social · Jul 3

Thrilled that our work on integrating genetic, contemporary and traditional risk factors into acute MI models has been published in
@CirculationGenomeandPrecisionMedicine @ahascience.bsky.social !!

Are genetic and contemporary risk factors as powerful as traditional RFs?

#CardioSky #cvPrev

Pradeep Natarajan @pnatarajanmd.bsky.social · Jul 3

Our study led by @romitb.bsky.social & C. Marnell shows that, when simultaneously considering clinical, laboratory, and genetic risk factors for incident CAD prediction, the top 2 model explanatory factors are:
1. Hypertension
2. CAD polygenic risk score
www.ahajournals.org/doi/10.1161/...

1 3 7

Satoshi Koyama @skoyama.bsky.social · Apr 18

I proudly advocate for 2002 as the year GWAS began 🙂
www.nature.com/articles/ng1...

Functional SNPs in the lymphotoxin-α gene that are associated with susceptibility to myocardial infarction - Nature Genetics

Nature Genetics - Functional SNPs in the lymphotoxin-α gene that are associated with susceptibility to myocardial infarction

www.nature.com

1 1 6

Reposted by Satoshi Koyama

Matt Sampson @kidneyomicsamps.bsky.social · Feb 23

This is the best article I’ve read so far in terms of describing the challenges impacting research in the US.

I am being directly affected already. My RO1 is due to be reviewed on Monday but the study section is likely to be canceled. This will have a profound impact on our lab’s work #kidneyomics

NPR @npr.org · Feb 22

The National Institutes of Health had to stop considering new grant applications, delaying funding for research into diseases ranging from heart disease and cancer to Alzheimer's and allergies.

NIH funding freeze stalls applications on $1.5 billion in medical research funds

The National Institutes of Health had to stop considering new grant applications, delaying funding for research into diseases ranging from heart disease and cancer to Alzheimer's and allergies.

www.npr.org

1 4 12

Reposted by Satoshi Koyama

Sri Kosuri @srikosuri.bsky.social · Feb 8

It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS or other (non-LCH) dendritic or histiocytic sarcomas cases.

83 860 1K

Reposted by Satoshi Koyama

PRIMED Consortium @prsmethods.bsky.social · Feb 3

📹🍿🧬 Check out @yunfeng-ruan.bsky.social's recent talk at the @broadinstitute.org, "Polygenic risk scores: method development and application" in our growing collection of videos on the @prsdiversity.bsky.social website primedconsortium.org/education#vi...

Education | PRIMED Consortium

primedconsortium.org

4 5

Satoshi Koyama @skoyama.bsky.social · Jan 24

Huge congrats! Satoshi😀

Satoshi Yoshiji, MD, PhD @satoshiyoshiji.bsky.social · Jan 24

📣Excited to share our paper in Nature Genetics!
rdcu.be/d7mo0

Do plasma proteins mediate obesity’s effect on CAD risk?

→Using two-step proteome-wide MR, domain-aware MR, epigenomics & scRNA-seq, we prioritized endotrophin, cleaved from COL6A3, as a mediator & potential therapeutic target.
A 🧵↓

1 2

Satoshi Koyama @skoyama.bsky.social · Jan 15

Many thanks to the team and the participants in
@ukbiobank.bsky.social for making this study possible.

@somijemmacho.bsky.social, Sara Haidermota, Whitney Hornsby, Patrick Ellinor, and @pnatarajanmd.bsky.social!

Satoshi Koyama @skoyama.bsky.social · Jan 15

10/ In summary:
Genetic predisposition to higher LDL-C → Lower T2D risk
No strong pathway-specific effects detected
Future research should refine mechanisms & mitigate risks

We are excited to contribute to this evolving discussion and look forward to future studies!

1 1

Satoshi Koyama @skoyama.bsky.social · Jan 15

9/ What’s next?
This study raises important questions about the mechanisms linking LDL-C and T2D. Further research is needed to:
🔍 Identify the specific pathways involved in this relationship
⚕️ Develop strategies to mitigate the risk.

1 1

Satoshi Koyama @skoyama.bsky.social · Jan 15

8/ Does this mean we should stop statins to prevent T2D?
🚫 Absolutely not.
Statins have clear cardiovascular benefits, and all randomized controlled trials consistently support their overall positive impact on health.

1 1

Satoshi Koyama @skoyama.bsky.social · Jan 15

7/ What does this mean?
A wide range of genetic predictions for LDL-C levels were significantly negatively associated with future T2D risk. These effects were not confined to specific pathways, which may imply a broader and more direct role of LDL-C in T2D susceptibility.

1 1

Satoshi Koyama @skoyama.bsky.social · Jan 15

6/ Interestingly, when we focused on individual variants within established cholesterol-regulating pathways (LDLR, PCSK9, HMGCR, NPC1L1), we did not find strong evidence for pathway-specific effects.

1 1

Satoshi Koyama @skoyama.bsky.social · Jan 15

5/ What did we find?
Higher genetic LDL-C is associated with a lower risk of T2D 📉
Lower genetic LDL-C is associated with a higher risk of T2D 📈
This effect was observed across various genetic predispositions.

1 2